EGFR and neoplasm: In Figures 1–5, we demonstrated that the activities of ERK1/2, AKT, mTOR, STAT3, and NFκB p65 were being decreased for at least 12 h by our (ruxolitinib + ERBB inhibitor) drug combination and we next determined the impact of pathway inactivation(s) on tumor cell viability.